Artera, a developer of multimodal artificial intelligence (MMAI)-driven prognostic and predictive cancer tests, has expanded its ArteraAI Prostate Test to include prostate cancer patients.
ArteraAI Prostate Test is an artificial intelligence (AI)-enabled test that uses patients’ digital biopsy images and clinical data to help predict treatment benefits.
The latest enhancement will help clinicians make better-informed decisions about active surveillance for prostate cancer patients.
ArteraAI Prostate Test is based on Artera’s advanced MMAI platform. It is said to be the first to both estimate the progression of a patient’s localised prostate cancer and predict the potential benefits of therapy.
Artera said that the test’s prognostic accuracy has been confirmed across a diverse patient population, including those who received active surveillance, radiation therapy, or radical prostatectomy.
The risk results provided by the test offer a comprehensive view of the patient’s prognosis, independent of the chosen treatment path.
The updated ArteraAI Prostate Test report now includes information on a patient’s relative risk of their cancer exhibiting more aggressive features, aiding in decisions about active surveillance.
The report offers clearer guidance on the suitability of this approach by comparing a patient’s risk to others managed under active surveillance.
Artera CEO Andre Esteva said: “With this expansion, we are proud to reinforce the reliability and robustness of the ArteraAI Prostate Test for a broader community of clinicians and patients.”
“Our mission is to empower all those delivering cancer care, from the laboratory to clinical practice, to realise the promise of precision medicine.”
Recently, PathNet, a digital pathology lab, incorporated the ArteraAI Prostate Test into its range of services.
The partnership expands the reach of the ArteraAI Prostate Test to PathNet’s network of over 200 clinics across 27 states.
Artera plans to further validate its MMAI platform and enhance the test report with new insights to bolster treatment decision-making for cancer patients.
The update to the test follows a February funding announcement in which Artera secured an additional $20m from large investment funds.
Furthermore, earlier this year, the ArteraAI Prostate test was included in the National Comprehensive Cancer Center (NCCN) guidelines for prostate cancer.
